This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Potassium bromide 200mg|
|Indication||For use with phenobarbitone as an aid in the treatment of refractory canine epilepsy. Potassium bromide should be used in conjunction with phenobarbitone when seizures continue despite persistent trough phenobarbitone levels above 30 microgram/mL for one or two months.Criteria for classifying idiopathic canine epileptics as refractory to phenobarbitone are: 1) seizure cause not identified; 2) phenobarbitone administered for at least three months with serum trough concentrations from 20 to 40 microgram/mL and a steady state trough concentration of 30 microgram/mL without a subsequent change in dosage for at least one month before bromide initiation; and 3) seizure number and severity unchanged for at least three months despite therapy.Bromide therapy can also be commenced if there is evidence of hepatotoxicity which requires reduction in dosage of the antiepileptic. Concurrent bromide therapy can result in partial or complete control of epileptic seizures in a high percentage of cases.|
|Contraindications||Safety in pregnant animals has not been undertaken and therefore the use of bromide in pregnant animals is contraindicated.|
|Precautions||First Aid If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.|
|Dosage and Administration||1 tablet/5 to 10 kg (20 to 40 mg/kg) daily, or in divided doses every 12 hours, with food. Select initial dose according to the degree of sedation experienced with concurrent therapy. After 30 days, adjust dosage according to serum bromide concentrations and clinical response.Maintaining therapeutic steady-state concentrations increases efficacy. Trough serum bromide and phenobarbitone concentrations should be measured at 30 and 120 days, and every six months during therapy or if adverse effects occur. Trough serum bromide concentrations should be between 0.7 and 2 mg/mL. Higher concentrations may result in sedation and ataxia. Concurrent trough serum phenobarbitone concentrations should be 25 to 30 microgram/mL. Liver function should also be monitored at these times. When bromide approaches steady-state concentrations in the therapeutic range and seizures are under control, reduction in phenobarbitone dosage can be attempted.|
|Storage||Store below 30°C (room temperature).|
|MSDS (external link)||Bromav Tablets MSDS|
|Label (external link)||Bromav Tablets Label|
|Manufacturer||Mavlab Pty Ltd|